Publication Topic

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.

Berger K, Rossi G, Orlando V, Fabry P, Jensen IS, Gallacher ME, et al. Mobilizing stem cells with plerixafor in MM patients: Impact on a health care provider’s budget in Germany and Italy. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2017.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615.

Young LY, Sacks NC, Cyr PL, Sharma A, Dahdal DN. 2017. Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy. Sage Open Med 5(Aug 31):2050312117727999; doi: 10.1177/205031211772799.

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5:212297; doi: 10.7573/dic.212297.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Wu E, Jensen IS, Cyr PL, Fan W, Mitchell M, Sulham K, Nathwani D. Use of oritavancin for the treatment of skin and soft tissue infections: A UK hospital budget impact analysis. ISPOR 20th Annual International Meeting, Philadelphia, PA, 2015.

Jensen I, Halbert R, Giuseppe R, Naoshy S, Iqbal SU, Zhimin X, McSweeney P. 2015. A hospital budget impact model to evaluate plerixafor in stem cell mobilization: Impact of primary research and direct stakeholder engagement. Eur J Hosp Pharm 22(3):142–149; doi: 10.1136/ejhpharm-2014-000543.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Cutler DM, Rosen AB. 2015. Recent national trends in acute myocardial infarction hospitalizations in Medicare: Shrinking declines and growing disparities [Letter to the Editor]. Epidemiol 26(4):e46–47; doi: 10.1097/EDE.0000000000000298.

Sacks NC, Burgess JF, Cabral HJ, McDonnell ME, Pizer SD. 2015. The effects of cost sharing on adherence to medications prescribed for concurrent use: Do definitions matter? J Manag Care Pharmacy 21(8):678–687.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Rosen AB. 2015. Trends in acute myocardial infarction hospitalizations: Are we seeing the whole picture? Am Heart J 170(6):1211-1219; doi: 10.1016/j.ahj.2015.09.009.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.